The FDA reviewed Pfizer’s mid-to-late stage clinical trials of Paxlovid and found “no evidence of a higher rate of symptom rebound or moderate symptom rebound.”
Read the full post on Becker's Hospital Review - Healthcare News
COVID-19 rebound not linked to Paxlovid, FDA says
